Raloxifene for the prevention and treatment of osteoporosis in post-menopausal women

Vitamin K is an essential fat soluble vitamin involved in the regulation of normal coagulation. However, growing evidence highlights that this molecule appears to be also implicated in the regulation of other important biological functions such as bone mineralization, calcium homeostasis, apoptosis, cell growth and signal transduction. In particular, many studies have focused their attention on the protective effects of vitamin K on bone tissue in the outlook of its use in the prevention and treatment of osteoporosis in post-menopausal women. The objective of the present paper is to review data of the literature regarding the metabolic effects of Vitamin K in bone tissue and its clinical role in the prevention and treatment of osteoporosis.

Download Full-text

Raloxifene for the prevention and treatment of osteoporosis in post-menopausal women

10.1002/14651858.cd003112.pub2 ◽

2007 ◽

Author(s):

Ann Cranney ◽

Vivian Welch ◽

Gordon H Guyatt ◽

N Krolicki ◽

Jonathan Adachi ◽

...

Keyword(s):

Treatment Of Osteoporosis ◽

Menopausal Women ◽

Prevention And Treatment ◽

Post Menopausal

Download Full-text

THE PROBLEM OF OSTEOPOROSIS IN MENOPAUSAL WOMEN AND POSSIBLE SOLUTIONS

Global problems of modernity ◽

10.26787/nydha-2713-2048-2021-2-1-15-17 ◽

2021 ◽

Vol 2 (1) ◽

pp. 15-17

Author(s):

Maiorova M.O.

Keyword(s):

Hormone Therapy ◽

Bone Tissue ◽

Calcium Metabolism ◽

Management Strategy ◽

Menopausal Hormone Therapy ◽

Effective Management ◽

Treatment Of Osteoporosis ◽

Menopausal Women ◽

Prevention And Treatment

41 women with osteoporosis were examined. The age of the examined people ranged from 50 to 60 years. All the women were postmenopausal. As a result of the study, it was found that the most effective management strategy for such patients is a combination of menopausal hormone therapy and non-hormonal drugs that affect calcium metabolism in bone tissue, improve its metabolism and reduce resorption. If there are contraindications to MGT, prevention and treatment of osteoporosis should also be carried out using the appointment of non-hormonal drugs. In this case, the use of ipriflavone is effective.

Download Full-text

Human parathyroid hormone for the treatment of osteoporosis in post-menopausal women.

10.1002/14651858.cd003111 ◽

2001 ◽

Author(s):

Lisa M. Waldegger ◽

Ann Cranney ◽

Jonathan Adachi ◽

Peter Tugwell ◽

George A Wells

Keyword(s):

Parathyroid Hormone ◽

Human Parathyroid Hormone ◽

Treatment Of Osteoporosis ◽

Menopausal Women ◽

Post Menopausal

Download Full-text

Different fracture risk profile in patients treated with anti-osteoporotic drugs in real-life

Reumatismo ◽

10.4081/reumatismo.2020.1267 ◽

2020 ◽

Vol 72 (2) ◽

pp. 71-74

Author(s):

G. Adami ◽

A. Giollo ◽

M. Rossini ◽

G. Orsolini ◽

C. Benini ◽

...

Keyword(s):

Fracture Risk ◽

Real Life ◽

Therapeutic Agents ◽

Risk Profile ◽

Routine Clinical Practice ◽

Baseline Risk ◽

Major Osteoporotic Fracture ◽

Treatment Of Osteoporosis ◽

Menopausal Women ◽

Post Menopausal

In this retrospective study, we intended to investigate the baseline fracture risk profile in patients who started treatment with different anti-osteoporotic medications. We analyzed retrospectively the fracture risk calculated with DeFRA, a validated FRAX derived tool, in women who started an anti-osteoporotic treatment from 2010 to 2017. We analyzed baseline data of 12,024 post-menopausal women aged over 50 years. Teriparatide initiators had a baseline 10-year risk of major osteoporotic fracture of 82.1% with a Standard Deviation (SD) of 66.5%. Denosumab initiators and zoledronic acid initiators had a greater 10-year baseline risk of fracture (54.3%, SD 46.5% and 47.0%, SD 42.0 respectively) than patients initiated on alendronate (24.9%, SD 34.6%) and patients initiated on risedronate (23.9%, SD 24.1%). Using DeFRA, a FRAX™ derived tool, we showed significantly different fracture risk profiles in women who were started on various therapeutic agents for the treatment of osteoporosis in routine clinical practice.

Download Full-text